skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Safety and efficacy of cilostazol in the management of intermittent claudication

Review

(2761) Views  (570) Full article downloads

Authors: Yung-Wei Chi, Carl J Lavie, Richard V Milani, Christopher J White

Published Date October 2008 Volume 2008:4(6) Pages 1197 - 1203
DOI: http://dx.doi.org/10.2147/VHRM.S3160

Yung-Wei Chi, Carl J Lavie, Richard V Milani, Christopher J White

Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA, USA

Abstract: Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.

Keywords: peripheral arterial disease, cilostazol, intermittent claudication, supervised exercise therapy








Readers of this article also read:
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University